Glaukos Corporation $GKOS Shares Bought by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP grew its stake in Glaukos Corporation (NYSE:GKOS) by 7.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,167,853 shares of the medical instruments supplier’s stock after purchasing an additional 83,669 shares during the quarter. Westfield Capital Management Co. LP owned approximately 2.04% of Glaukos worth $120,628,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GKOS. Nuveen LLC purchased a new stake in Glaukos during the 1st quarter valued at about $31,474,000. Ehrlich Financial Group purchased a new stake in Glaukos in the 2nd quarter valued at about $1,034,000. Royal Bank of Canada raised its position in Glaukos by 103.2% in the first quarter. Royal Bank of Canada now owns 228,249 shares of the medical instruments supplier’s stock valued at $22,464,000 after purchasing an additional 115,939 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Glaukos in the 1st quarter valued at $307,000. Finally, LPL Financial LLC increased its position in shares of Glaukos by 25.1% during the first quarter. LPL Financial LLC now owns 15,775 shares of the medical instruments supplier’s stock worth $1,553,000 after acquiring an additional 3,163 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Trading Up 5.4%

NYSE:GKOS opened at $96.55 on Thursday. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $163.71. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $84.23 and a 200-day simple moving average of $91.29. The company has a market capitalization of $5.55 billion, a PE ratio of -62.70 and a beta of 0.81.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.53%. The firm had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. During the same period last year, the firm posted ($0.28) EPS. The firm’s revenue for the quarter was up 38.1% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on GKOS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. JPMorgan Chase & Co. boosted their price target on shares of Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Needham & Company LLC raised their price objective on shares of Glaukos from $115.00 to $117.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, Citigroup boosted their target price on Glaukos from $110.00 to $113.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $119.08.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.